Fluconazole
Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent
Explore 3 assets in Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fluconazole (this asset) | Children's Oncology Group | P3 | BB · 64 |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BB |
| Azacitidine | National Cancer Institute (NCI) | P2 | BB |
| Cytarabine | National Cancer Institute (NCI) | P2 | BB |
| Caspofungin | Children's Oncology Group | P3 | BB |
| Lenalidomide | M.D. Anderson Cancer Center | P2 | B |
| Decitabine | Roswell Park Cancer Institute | P2 | B |
| Fludarabine | National Cancer Institute (NCI) | P2 | B |
| Tacrolimus | National Cancer Institute (NCI) | P2 | B |
+12 more in the Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent cohort
Other indications for Fluconazole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Candidiasis, Invasive | — | P4 | BB · 69 |
| Systemic Mycosis | — | P4 | BB · 69 |
| Infectious Disease | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- AzacitidineNational Cancer Institute (NCI)BB
- CytarabineNational Cancer Institute (NCI)BB
- CaspofunginChildren's Oncology GroupBB
- LenalidomideM.D. Anderson Cancer CenterB
Citation
Floatz Terminal. Fluconazole in Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fluconazole-acute-myeloid-leukemia-and-myelodysplastic-syndromes-related-to-alkylating-agent
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →